Skip to content

Multimodal Therapeutic Approach in Undernourished Maintenance Hemodialysis Patients (AMERICANO)

Multimodal Therapeutic Approach by Exercise, Oral Nutritional Supplementation, Omega 3 and Androgen in Undernourished Maintenance Hemodialysis Patients (AMERICANO)

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02418065
Acronym
AMERICANO
Enrollment
120
Registered
2015-04-16
Start date
2013-12-31
Completion date
2017-04-30
Last updated
2016-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Failure

Keywords

Physical exercises, Oral nutritional supplementation, Multimodal, Hemodialysis, Protein-Energy Wasting

Brief summary

The aim of the study is to evaluate a 3 months integrated multimodal therapeutic approach including exercise training program with ergocycle during dialysis sessions, oral nutritional supplementation, omega 3 and androgen, on effort tolerance and quality of life of under-nourish maintenance hemodialysis Chronic Kidney Disease (CKD) patient.

Detailed description

The aim of the study is to evaluate a 3 months integrated multimodal therapeutic approach including exercise training program with ergocycle during dialysis sessions, oral nutritional supplementation, omega 3 and androgen, on effort tolerance and quality of life of under-nourish maintenance hemodialysis Chronic Kidney Disease (CKD) patient.

Interventions

OTHERtraining on ergonomic bicycle
DRUGTestosterone
DRUGn3 polyunsaturated fatty acid

Sponsors

Human Nutrition Research Center Rhône-Alpes
CollaboratorUNKNOWN
Société Francophone Nutrition Clinique et Métabolisme
CollaboratorOTHER
Nutricia, Inc.
CollaboratorINDUSTRY
University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hemodialysis patient since at least 6 month * Patient aged 18 years or older * Written consent to participate in the study * No acute infection or hospitalization * Opinion of Cardiologist saying there is no known evidence against the evaluation of the maximum exercise capacity * Protein-energy wasting diagnosed if at least two of this characteristics are present * Serum albumin \<3.8 g per 100 ml (Bromcresol Green) * Serum prealbumin (transthyretin) \<30mg per 100 ml * Reduce body mass (BMI \<23) * Unintentional 10% weight loss over 6 months * Lean body mass index \< 10th percentile

Exclusion criteria

* Presence of comorbidity which compromising the survival within 6 month * Unintentional low DEI \<20 kcal kg\_1 day\_1 * HIV or HCV positive * History of hormone dependent cancer * Suspected or confirmed prostate cancer or breast carcinoma * Known hypersensitivity for testosterone * Presence or history of hepatic tumor * Inability to follow the rehabilitation program * Inadequate dialysis dosage (\<12 hours / week or Kt/V index\< 1,2) Pregnant or planning pregnancy and lactating women during study period * Adult patient protected by law * Patient who don't sign his informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change of physical endurance on bicycleAt months 3 and 15 after inclusionPhysical endurance on bicycle at intermediate power between maximal power and ventilatory threshold power (Pmax+Pthreshold)/2

Secondary

MeasureTime frameDescription
Health-related quality of life assessment using SF-36 scale and KDQOLat day 1
Karnofsky scoreat ady 1
Maximal power on bicycleat day 1Unit of Measure: Watt
Nutritional parametersat day 1weight (Kg)
Transthyrin serum concentration evolutionat day 1(Unit of Measure: g/L)
determination of urea (mmol/L)at day 1
determination of creatinine(µmol/L)at 1 year
Body compositionat day 1(evaluated by bioimpedance)
serum levels of albumin (g/L)at day 1

Countries

France

Contacts

Primary ContactPatrick LACARIN
placarin@chu-clermontferrand.fr04 73 75 11 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026